10
April
Thursday (Online Day)
ONLINE SESSIONS
(Lectures in English)
(Lectures in English)
10:00am
- 1:15am
Genetic and Molecular Determinants in Cancer: From Hereditary Mutations to Therapeutic Interventions
This title captures the range of topics covered in the
session, which includes:
- Population screening for founder mutations
BRCA mutations in breast cancer
- Biomarkers and trace
elements in prostate cancer
- Selenium-based risk
reduction strategies for hereditary breast cancers
- Molecular mechanisms in neuroblastoma
treatment
- Immune cell generation in melanoma
The title reflects both the
genetic aspects (mutations, hereditary factors) and molecular elements (trace
elements, gangliosides, immune cells) that are discussed across different
cancer types during this session.
Moderators
10:00am
- 10:25am
Population screening for founder mutations conferring high cancer risk in Poland
Lecturer
Cezary Cybulski
10:25am
- 10:50am
BRCA1 and BRCA2 Mutations in Polish Women with Ductal Carcinoma In situ
Lecturer
10:50am
- 11:15am
Serum Copper, Zinc Levels and Copper/Zinc ratio in Prostate Cancer Patients Survival
Lecturer
Sandra Pietrzak
11:15am
- 11:40am
SELINA – lowering cancer risk in females from families with hereditary breast cancers by As-low diet and optimization of blood Se levels by diet or supplementation
Lecturer
11:40am
- 12:05am
Phenotypic and molecular changes induced in human neuroblastoma cells by GD2 ganglioside-recognizing therapeutic antibodies
Lecturer
Hanna Rokita
12:05pm
- 12:30pm
Generation of MDSC from Normal Monocytes in Melanoma
Lecturer
12:30pm
- 12:55pm
The Role of Blood Zinc-to-Copper Ratio as a Potential Biomarker of Cancer Risk in BRCA1 Mutation Carriers
Lecturer
Milena Matuszczak
12:55pm
- 1:15pm
Discussion
1:15pm
- 2:00pm
Break
2:00pm
- 4:30pm
Tumor Microenvironment Modulation and Novel Therapeutic Approaches: From Immune Reprogramming to Nanomedicine
This title captures the central themes of the session,
which focuses on:
- Reprogramming tumor
microenvironments to enhance immune responses
- Manipulation of
immune trafficking and signaling in various cancers
- Novel therapeutic
modalities including exosome targeting, photothermal therapy, and
oligonucleotide-based approaches
- Molecular mechanisms
underlying cancer cell biology and treatment resistance
The title reflects both the
focus on tumor microenvironment manipulation and the diverse innovative
therapeutic strategies presented by researchers from institutions across the
United States.
Moderators
2:00pm
- 2:25pm
Reprogramming the Perivascular Tumor Microenvironment to Facilitate Tumoricidal T-cell Trafficking into Metastasis of Ovarian Cancer
Lecturer
2:25pm
- 2:50pm
Systemic Infusion of a TLR3 ligand (Rintatolimod) and IFNa2b selectively reprograms tumor microenvironments for local CTL influx: Combinations with PD1/PDL1 blockade and chemotherapies
Lecturer
2:50pm
- 3:15pm
The role of melanoma-derived exosomes in immune-oncology
Lecturer
3:15pm
- 3:40pm
Toward cancer therapy with electromagnetics and nanoparticles
Lecturer
3:40pm
- 4:05pm
Temperature and WNK-SPAK/OSR1 kinases dynamically regulate structure of biomolecular condensates in cancer cells
Lecturer
4:05pm
- 4:30pm
Thiopurine-Based Oligonucleotides for Targeted Telomere Damage and Immunotherapy of Leukemia and Lymphoma
Lecturer
11
April
Friday (Stationary Day)
9:00am
- 10:05am
Non-melanoma skin cancers
Moderators
Marcin Ziętek
Jacek Mackiewicz
9:00am
- 9:15am
Squamous cell carcinoma progression model. Dermatoscopic images (AK, BD, SCC)
Lecturer
Jacek Calik
9:15am
- 9:30am
Surgical treatment of skin cancers - Standards of procedure and limitations of intervention
Lecturer
Marcin Ziętek
9:30am
- 9:45am
The place of radiotherapy in the treatment of skin cancer patients
Lecturer
9:45am
- 10:00am
Advances in systemic treatment for skin cancer patients
Lecturer
Izabela Łasińska
10:00am
- 10:05am
Discussion
10:05am
- 10:15am
Break
10:15am
- 11:35am
Immunology and immunotherapy of cancer - Session of the Immuno-oncology Section of the Polish Oncological Society
Moderators
Bożena Cybulska-Stopa
Jacek Mackiewicz
10:15am
- 10:30am
The role of different lymphocyte populations in the antitumor response in patients undergoing ICI therapy
Lecturer
Mariusz Kaczmarek
10:30am
- 10:45am
Biomarkers of response to immunotherapy
Lecturer
Anna Czarnecka
10:45am
- 11:00am
Biomarkers of immunotherapy toxicity
Lecturer
Grażyna Kamińska-Winciorek
11:00am
- 11:15am
The role of microbiota in cancer therapy
Lecturer
Marcin Schmidt
11:15am
- 11:30am
Immunotherapy after previous immunotherapy in cancer patients
Lecturer
Bożena Cybulska-Stopa
11:30am
- 11:35am
Discussion
11:35am
- 11:45am
Break
11:45am
- 1:05am
Lung cancer
Moderators
Rodryg Ramlau
11:45am
- 12:00am
Advances in Perioperative Treatment of NSCLC Patients
Lecturer
Mateusz Polaczek
12:00pm
- 12:15pm
Lecture under the patronage of 
Selection of systemic therapy in patients with advanced NSCLC with PDL1 expression ≥ 1%
Selection of systemic therapy in patients with advanced NSCLC with PDL1 expression ≥ 1%
Lecturer
Adam Płużański
12:15pm
- 12:30pm
Lecture under the patronage of 
Selection of systemic therapy in patients with advanced NSCLC with PDL1 expression <1%
Selection of systemic therapy in patients with advanced NSCLC with PDL1 expression <1%
Lecturer
Maciej Bryl
12:30pm
- 12:45pm
Lecture sponsored by 
Molecularly Targeted Treatment for Advanced NSCLC - State of the Art 2025
Molecularly Targeted Treatment for Advanced NSCLC - State of the Art 2025
Lecturer
12:45pm
- 1:00pm
Is it possible to monitor the quality of care in lung cancer? - own experience of DCOPiH in Wroclaw
Lecturer
Adam Maciejczyk
1:00pm
- 1:05pm
Discussion
1:05pm
- 1:45pm
Lunch
9:00am
- 10:45am
Molecular mechanisms in cancer biology and treatment resistance
This session explores fundamental cellular
and molecular processes underlying cancer development and therapeutic
resistance. Presentations examine:
- various molecular targets and pathways,
including the role of nanomaterials in treatment, dormancy mechanisms in lung
carcinoma,
- novel anthracycline development,
- apoptosis resistance mechanisms,
- genetic interactions in ovarian cancer.
The session offers insights into both
basic cancer biology and translational approaches for overcoming treatment
resistance at the molecular level.
Moderators
Michael Giersig
9:00am
- 9:15am
Magnetic nanomaterials as a multifunctional platform for cancer treatment
Lecturers
Magdalena Osial
Michael Giersig
9:15am
- 9:30am
ZNF273 contributes to dormancy phenotype in squamous cell lung carcinoma
Lecturer
9:30am
- 9:45am
Organotropic Targeting of Pancreatic Cancer with Annamycin, a Non-Cardiotoxic Anthracycline
Lecturer
9:45am
- 10:00am
Galactosylceramide increases the resistance of breast cancer cells to apoptosis through EGFR signaling pathway
Lecturers
Safoura Reza
10:00am
- 10:15am
Novel molecular interactions in high-grade serous ovarian cancer
Lecturer
10:15am
- 10:30am
Role of calpains in preventing leukemic cells from apoptosis and affecting the activity of lymphocytes
Lecturer
10:30am
- 10:45am
Discussion
10:45am
- 11:00am
Coffee Break
11:00am
- 1:00am
Tumor microenvironment and innovative treatment approaches
This session focuses on the complex tumor
system and novel therapeutic strategies that target the microenvironment.
Presentations highlight:
- the critical role of hypoxia in cancer
progression and treatment response,
- immune cell dynamics during melanoma
therapy,
- innovative bioengineering approaches for
studying angiogenesis,
- oxygen heterogeneity in tumor models,
- nanocarrier-based vascularization targeting.
T
The session culminates with an examination
of the intricate relationships between immune status, viral infection history,
and immunotherapy efficacy, providing a comprehensive overview of how
microenvironmental factors influence cancer treatment outcomes.
Moderators
11:00am
- 11:15am
Hypoxia-dependent diseases: cell-gene therapy for vessel normalization in tumor and degenerescence diseases
Lecturer
11:15am
- 11:30am
iPSC-Derived Vascular Grafts for 3D Bioprinting and Angiogenesis
Lecturer
11:30am
- 11:45am
Heterogeneity of tumor oxygenation in murine models
Lecturer
11:45am
- 12:00am
Spatial Transcriptomics: Insights from Mouse and Human Adrenal Glands and Its Application in Tumor Microenvironment Profiling
Lecturer
12:00pm
- 12:15pm
Silk nanocarrier-based strategies targeting tumor vascularization in non-small cell lung cancer treatment
Lecturer
Anna Florczak
12:15pm
- 12:30pm
The complex interplay between autoimmune diathesis, Herpes virus infection history, trained immunity, and cancer's mutational profile shapes the effect of cancer immunotherapy
Lecturer
12:30pm
- 12:45pm
Molecular mechanisms of action of a genetically modified melanoma cell vaccine
Lecturer
Mariusz Kaczmarek
12:45pm
- 1:00pm
Discussion
1:00pm
- 1:45pm
Lunch
PLENARY SESSION
(Lectures in Polish)
(Lectures in Polish)
1:45pm
- 2:00pm
OPENING CEREMONY OF THE CONFERENCE
Lecturers
2:00pm
- 4:00pm
Health and economic security of the EU through the lens of oncology research and enhancing the competitiveness of the biotechnology and pharmaceutical sector
Moderator
I. How to combine health security with economic security?:
Health and economic security in the light of challenges and changes in EU development priorities
Lecturer
Europe’s Beating Cancer Plan - progress and challenges. Perspective of the SANT Committee of the EP
Lecturer
Biotechnological innovations in oncology - how to break down barriers and accelerate development?
Lecturer
From good basic research to innovative products for oncology - what is missing and what to do about it?
Lecturer
II. Complementary or competitive? How to support science and business?:
Mechanisms for supporting biomedical oncology projects by the Medical Research Agency
Lecturer
Instruments of the Foundation for Polish Science in oncology development
Lecturer
From research institute - through center of excellence - to Excellence Hub
Strengthening chances for success in Horizon Europe. Cluster Health, Cancer Mission, European Partnerships
Lecturer
Drug Discovery in Academia: Importance of Translational Research and International Collaboration
Lecturer
Challenges faced by a scientist starting work at a biotechnology company
Lecturer
Rafał Derlacz
III. Implementations. Examples of successes and challenges:
Development of cancer vaccines. Reality, potential and challenges on the example of the melanoma vaccine AGI-101 H
Lecturer
Development of genetics and development of personalized medical care in oncology - communicating vessels?
Lecturer
Achievements of the Institute of Human Genetics of the Polish Academy of Sciences in cancer research
Lecturer
Discussion
4:00pm
- 4:15pm
Break
4:15pm
- 5:50pm
Genitourinary cancers
Moderators
Piotr Milecki
Jakub Kucharz
4:15pm
- 4:30pm
Adjuvant treatment for kidney cancer patients
Lecturer
Daria Tusień-Małecka
4:30pm
- 4:45pm
Lecture under the patronage of
Principles of qualifying kidney cancer patients for first-line systemic treatment
Principles of qualifying kidney cancer patients for first-line systemic treatment
Lecturer
Jakub Kucharz
4:45pm
- 5:00pm
Lecture sponsored by 
Current systemic treatment options in Poland for prostate cancer patients
Current systemic treatment options in Poland for prostate cancer patients
Lecturer
Paweł Wiechno
5:00pm
- 5:15pm
Lecture under the patronage of 
Advanced urothelial tumors - current treatment options and perspectives
Advanced urothelial tumors - current treatment options and perspectives
Lecturer
Piotr Tomczak
5:15pm
- 5:30pm
Recurrence after local treatment - Role of adjuvant/salvage radiotherapy alone/combined with androgen deprivation
Lecturer
Piotr Milecki
5:30pm
- 5:45pm
Lecture sponsored by 
Targeted radioligand therapy in patients with prostate cancer
Targeted radioligand therapy in patients with prostate cancer
Lecturer
Jakub Kucharz
5:45pm
- 5:50pm
Discussion
6:00pm
- 7:15pm
Non-Hodgkin's lymphoma (NHL): from diagnosis to advanced therapeutic strategies
Moderators
Lidia Gil
Krzysztof Lewandowski
6:00pm
- 6:15pm
A new approach to the diagnosis of NHL
Lecturer
Monika Prochorec-Sobieszek
6:15pm
- 6:30pm
Application of whole-genome sequencing in the analysis of lymphoproliferative tumors
Lecturer
6:30pm
- 6:45pm
B-specific T-cell engaging (BiTE) monoclonal antibodies in NHL therapy
Lecturer
Wojciech Jurczak
6:45pm
- 7:00pm
Chimeric antigen receptor T cells (CART) in NHL therapy
Lecturer
Lidia Gil
7:00pm
- 7:10pm
Evaluation of the response to the applied treatment in NHL - PET CT
Lecturer
7:10pm
- 7:15pm
Evaluation of the response to the applied treatment in NHL - molecular techniques
Lecturer
Krzysztof Lewandowski
7:15pm
- 7:30pm
MIR142 – the most frequently mutated miRNA gene in cancer
Lecturer
Paulina Gałka-Marciniak
4:15pm
- 6:30pm
From the Laboratory to the Clinic - How to successfully co-create medical innovations?
6:30pm
- 7:15pm
Session of awarded posters
Moderator
HDAC9 as a potential modulator of the MAPK signaling in Sézary Syndrome Pathogenesis
Monika Pieniawska
Impact of silencing the ZNF714 and ZNF695 genes on the stiffness of lung cancer cells
Anna Bisok
siRNA_STAT3 targeted delivery by silk nanocarriers: a strategy to address chemotherapy resistance in Her2-/Her2+ breast cancer
Sara Molenda
Double-functionalized silk nanospheres for delivery of therapeutic oligonucleotides to VEGFR-overexpressing cells of the tumor microenvironment
Patryk Lorenc
Discussion
12
April
Saturday (Stationary Day)
9:00am
- 10:20am
Breast cancer
Moderators
Barbara Radecka
Joanna Kufel-Grabowska
9:00am
- 9:15am
Axillary Surgery: Current management of positive sentinel node biopsy
Lecturer
Mateusz Wichtowski
9:15am
- 9:30am
Systemic treatment of patients with HER2-negative luminal breast cancer
Lecturer
Daria Świniuch
9:30am
- 9:45am
Systemic treatment of patients with triple-negative breast cancer
Lecturer
Barbara Radecka
9:45am
- 10:00am
Systemic treatment of patients with HER2 positive breast cancer
Lecturer
Elżbieta Senkus-Konefka
10:00am
- 10:15am
Pregnancy after cancer: opportunities and challenges
Lecturer
Joanna Kufel-Grabowska
10:15am
- 10:20am
Discussion
10:20am
- 10:30am
Break
10:30am
- 12:00am
Melanoma
Moderators
Piotr Rutkowski
Jacek Mackiewicz
10:30am
- 10:45am
Strategy to limit surgical treatment in melanoma patients
Lecturer
Piotr Rutkowski
10:45am
- 11:00am
Lecture under the patronage of
Criteria for the selection of systemic treatment in patients with metastatic melanoma
Criteria for the selection of systemic treatment in patients with metastatic melanoma
Lecturer
Jacek Mackiewicz
11:15am
- 11:30am
Lecture sponsored by
Advances in the Treatment of Melanoma Patients with Brain Metastases
Advances in the Treatment of Melanoma Patients with Brain Metastases
Lecturer
Anna Czarnecka
11:30am
- 11:40am
Lecture sponsored by
Polish results of iBRAF+MEK treatment in patients with advanced melanoma
Polish results of iBRAF+MEK treatment in patients with advanced melanoma
Lecturer
Anna Czarnecka
11:40am
- 11:55am
Advances in Cell Therapies for Melanoma Patients
Lecturer
Tomasz Świtaj
11:55am
- 12:00am
Discussion
12:00pm
- 12:35pm
Brain tumors
Moderators
Sergiusz Nawrocki
Jakub Moskal
12:00pm
- 12:15pm
Lecture sponsored by 
Advances in Surgical Treatment of Primary Brain Tumors
Advances in Surgical Treatment of Primary Brain Tumors
Lecturer
Jakub Moskal
12:15pm
- 12:30pm
Lecture sponsored by
New methods of treating primary and secondary tumors of the central nervous system
New methods of treating primary and secondary tumors of the central nervous system
Lecturer
Sergiusz Nawrocki
12:30pm
- 12:35pm
Discussion
12:35pm
- 12:45pm
Break
12:45pm
- 2:05pm
Gastrointestinal cancers
Moderators
Rafał Stec
Tomasz Kubiatowski
12:45pm
- 1:00pm
Lecture under the patronage of
Advances in systemic treatment of patients with esophageal and stomach cancer
Advances in systemic treatment of patients with esophageal and stomach cancer
Lecturer
Rafał Stec
1:00pm
- 1:15pm
Principles of perioperative treatment in patients with rectal cancer
Lecturer
Marek Gełej
1:15pm
- 1:30pm
How to choose the right first-line therapy for metastatic colorectal cancer patients
Lecturer
Tomasz Kubiatowski
1:30pm
- 1:45pm
Lecture sponsored by
Systemic treatment after failure of first-line therapy in patients with colorectal cancer
Systemic treatment after failure of first-line therapy in patients with colorectal cancer
Lecturer
Leszek Kraj
1:45pm
- 2:00pm
Lecture sponsored by 
Dermatological complications in patients treated with anti-EGFR antibodies
Dermatological complications in patients treated with anti-EGFR antibodies
Lecturer
Magdalena Ciążyńska
2:00pm
- 2:05pm
Discussion
9:00am
- 11:40am
Emerging technologies in cancer diagnostics and therapy
This session explores how technological
innovations are transforming cancer care across the diagnostic-therapeutic
continuum. Presentations cover:
- myeloid cell targeting in brain tumors
- the evolution from basic to clinical
pathology applications,
- IT solutions for international
collaboration,
- multi-omics approaches in leukemia
research,
- molecular characterization of salivary
gland tumors,
- CAR-T cell therapy development through
academic-industry partnerships,
- artificial intelligence applications in
oncology, and advanced mass spectrometry tools for proteomics.
The session demonstrates how technological
convergence is driving next-generation cancer diagnostics and therapeutics
through interdisciplinary approaches.
Moderators
Andrzej Marszałek
9:00am
- 9:15am
Targeting arginase 1 in myeloid cells in preclinical models of brain tumors
Lecturer
9:15am
- 9:30am
Uveal melanoma and skin melanoma – similarities and differences
Lecturer
9:30am
- 9:45am
From basic to clinical research - PATHOMORPHOLOGY
Lecturer
Andrzej Marszałek
9:45am
- 10:00am
Optimal preclinical models and cancer heterogeneity- challenges for cancer immunotherapy
Lecturer
10:00am
- 10:15am
Development of IT based communication technologies (technical and regulatory aspects) for medical data and biological material exchange during international collaboration (Project ATTICA)
Lecturer
10:15am
- 10:30am
Multiomics approach in search for alternative mechanisms leading to activation of JAK-STAT pathway in T-cell acute lymphoblastic leukemia
Lecturer
10:30am
- 10:45am
Recurrent TERT rearrangements in mucoepidermoid carcinoma
Lecturer
10:45am
- 11:00am
Advancing CAR-T-based cancer therapies. Synergy of translational research and academia-industry collaboration
Lecturers
Natalia Rozwadowska
Tomasz Kolanowski
11:00am
- 11:15am
AI, Machine Learning, and Radiomics for Enhanced Cancer Diagnosis and Treatment
Lecturer
11:15am
- 11:30am
Universal toolset for mass spectrometric analysis of intracellular peptidome and small protein fraction
Lecturer
11:30am
- 11:40am
Discussion
11:40am
- 11:50am
Coffee Break
11:50am
- 1:35am
Advances in Radiotherapy and Precision Oncology
This session showcases
cutting-edge developments in radiation oncology and personalized cancer
treatment. Presentations address:
- intraoperative radiotherapy's effects on
the post-surgical wound microenvironment,
- personalization strategies for
conventional and proton therapy in breast cancer,
- ultra-high dose-rate radiobiology (FLASH
therapy),
- quality improvement initiatives through
international clinical audits,
- dosimetry considerations for organs at
risk,
- and molecular aspects of breast cancer
therapy resistance.
The session highlights Poland's
significant contributions to advancing precision radiotherapy and treatment
optimization.
Moderators
11:50am
- 12:05am
Intraoperative radiation therapy as a factor reducing the tumorigenic potential of breast cancer cells by modifying the microenvironment of the postoperative wound
Lecturers
12:05pm
- 12:20pm
Radiotherapy and protontherapy personalisation in breast cancer based on individuals’ predispositions (project PROBREST)
Lecturer
12:20pm
- 12:35pm
Impact of ultrahigh dose-rates on biological response in radiotherapy (Projekt AQURE FLASH)
Lecturer
12:35pm
- 12:50pm
Improving quality of radiation oncology in rectal and prostate cancer using international clinical audits (project IROCA)
Lecturer
Magdalena Fundowicz
12:50pm
- 1:05pm
Low doses in peripheral organs during radiotherapy of prostate cancer” (project LOWDOSE)
Lecturer
1:05pm
- 1:20pm
Molecular aspects of breast cancer cell resistance to anticancer therapy
Lecturer
1:20pm
- 1:35pm
Discussion and closing remarks